Celltrion started to support all-around support, including investments in global bio-health care companies, for the Incheon Songdo biocluster construction support project.
Celltrion signed a business agreement (MOU) with Sartorius, a global biopharmaceutical company, which decided to build a biopharmaceutical raw and subsidiary material manufacturing facility last month by investing 100 million dollars (about 1084 billion won) in Songdo, Incheon.
In addition, it is accelerating investment discussions in various manufacturing and service supply facilities in Songdo, Incheon with global healthcare companies such as ThermoFisher Scientific, Avantor, and Cytiva.
Thermofisher Scientific is a global healthcare company headquartered in Waltham, Massachusetts, USA. It supplies life science products and related technology services to the world, including Korea, and is considering investment in badge manufacturing facilities and distribution centers in Korea. .
Headquartered in Pennsylvania, USA, Avanto is a global company that supplies products and services in the fields of life sciences, chemicals, and advanced materials.
Celltrion’s main source of commercial drugs·Sitiba, a supplier of subsidiary materials, is also a global company that supplies products and services for biopharmaceutical research, development, and production.In 2016, the APAC Fast Trak Center, which is in charge of biopharmaceutical production process optimization services and process related education It has been established and is actively operating. Since the recent spin-off from GE Healthcare, it has been working closely with Celltrion to establish additional investment plans in the Songdo area.
Celltrion is an important bio source·When companies with global level production and supply capabilities for subsidiary materials make investments in various manufacturing facilities and distribution warehouses in the biocluster centered on Songdo, Incheon, domestic bio companies are an important source.·It is expected that subsidiary materials and service services will be provided more stably.
An official from Celltrion said, “As the demand for raw and subsidiary materials from bio companies around the world has exploded in the aftermath of the global Corona 19 pandemic,·“The stable procurement of subsidiary materials has become more important than ever.”·An important core source by discovering subsidiary materials companies and actively supporting them, while actively attracting manufacturing facilities of overseas global companies.·He said, “We will work hard to break away from the dependence of subsidiary materials overseas and establish a stable supply system.”